Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

Abstract : One-third of patients aged ≤60 years with aggressive lymphoma are at low-intermediate risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a similar regimen including epirubicin instead of doxorubicin and increased dose intensity of cyclophosphamide, followed by conventional consolidation with an increased amount and dose intensity of cytosine-arabinoside, methotrexate, etoposide, and ifosfamide, in 652 patients with LIR aggressive lymphoma. The overall response rate, 5-year event-free survival (EFS), and survival were estimated to be 86%, 60%, and 74%, respectively, with no differences between the two arms. In patients with diffuse large B-cell lymphoma (DLBCL) who received ACVBP, the 5-year EFS and survival were estimated at 69% and 82%. These findings do not support the use of a chemotherapy regimen more intensive than ACVBP in patients aged ≤60 years with LIR aggressive lymphoma. The results in the control arm, without rituximab, have led to a randomized comparison of R-ACVBP and R-CHOP in this patient population.
Type de document :
Article dans une revue
Leukemia & lymphoma, Taylor & Francis, 2010, 51 (9), pp.1668-1677. 〈10.3109〉
Liste complète des métadonnées

https://hal-ens-lyon.archives-ouvertes.fr/ensl-00817207
Contributeur : Agnès Ganivet <>
Soumis le : mercredi 24 avril 2013 - 09:56:07
Dernière modification le : vendredi 8 juin 2018 - 14:34:03

Identifiants

  • HAL Id : ensl-00817207, version 1
  • DOI : 10.3109

Collections

Citation

Pierre Morel, Jean-Nicolas Munck, Bertrand Coiffier, Christian Gisselbrecht, Dana Ranta, et al.. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia & lymphoma, Taylor & Francis, 2010, 51 (9), pp.1668-1677. 〈10.3109〉. 〈ensl-00817207〉

Partager

Métriques

Consultations de la notice

133